These findings establish salvigenin as a potent therapeutic agent in HCC, capable of reversing 5‐FU resistance and impairing tumor growth through suppression of the PI3K/AKT/GSK‐3β axis and glycolytic metabolism. This evidence concerns the gene GSK3B and hepatocellular carcinoma.